» Articles » PMID: 23360848

Perifosine and Sorafenib Combination Induces Mitochondrial Cell Death and Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2013 Jan 31
PMID 23360848
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of the Akt inhibitor perifosine and the RAF/MEK/ERK inhibitor sorafenib were investigated using two CD30(+)Hodgkin lymphoma cell lines (L-540 and HDLM-2) and the CD30(-)HD-MyZ histiocytic cell line. The combined perifosine/sorafenib treatment significantly inhibited mitogen-activated protein kinase and Akt phosphorylation in two of the three cell lines. Profiling of the responsive cell lines revealed that perifosine/sorafenib decreased the amplitude of transcriptional signatures that are associated with the cell cycle, DNA replication and cell death. Tribbles homolog 3 (TRIB3) was identified as the main mediator of the in vitro and in vivo antitumor activity of perifosine/sorafenib. Combined treatment compared with single agents significantly suppressed cell growth (40-80%, P<0.001), induced severe mitochondrial dysfunction and necroptotic cell death (up to 70%, P<0.0001) in a synergistic manner. Furthermore, in vivo xenograft studies demonstrated a significant reduction in tumor burden (P<0.0001), an increased survival time (81 vs 45 days, P<0.0001), an increased apoptosis (2- to 2.5-fold, P<0.0001) and necrosis (2- to 8-fold, P<0.0001) in perifosine/sorafenib-treated animals compared with mice receiving single agents. These data provide a rationale for clinical trials using perifosine/sorafenib combination.

Citing Articles

Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment.

Zhuang T, Wang S, Yu X, He X, Guo H, Ou C Biomark Res. 2024; 12(1):88.

PMID: 39183323 PMC: 11346179. DOI: 10.1186/s40364-024-00639-0.


Establishing a novel and sensitive assay for bioactivity determination of anti-CD25 antibodies.

Duan M, Yu C, Yang Y, Fu Z, Liu C, Du J Heliyon. 2023; 9(6):e17401.

PMID: 37416689 PMC: 10320283. DOI: 10.1016/j.heliyon.2023.e17401.


Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells.

Adamova B, rihova K, Pokludova J, Benes P, Smarda J, Navratilova J J Cell Mol Med. 2022; 27(1):76-88.

PMID: 36523175 PMC: 9806293. DOI: 10.1111/jcmm.17636.


Microarray analysis of breast cancer gene expression profiling in response to 2-deoxyglucose, metformin, and glucose starvation.

Aoun R, El Hadi C, Tahtouh R, El Habre R, Hilal G Cancer Cell Int. 2022; 22(1):123.

PMID: 35305635 PMC: 8933915. DOI: 10.1186/s12935-022-02542-w.


KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.

Vendramini E, Bomben R, Pozzo F, Bittolo T, Tissino E, Gattei V Cancers (Basel). 2022; 14(3).

PMID: 35158933 PMC: 8833570. DOI: 10.3390/cancers14030666.